1.Advancement in stimuli-sensitive drug delivery system
International Journal of Biomedical Engineering 2011;34(6):367-370
Stimuli-sensitive drug delivery system (SSDDS) is an novel drug delivery carrier.It is sensitive to either the internal physiopathologic changes (pH,temperature) of the body or external stimulus signal (ultrasound,magnetic signal) and controls the release of the drugs that it carries according to the variation of physicochemical property which stimulated by the signals.SSDDS can be prepared from hydrogels,liposomes and magnetic nanoparticles.In contrast to non-stimuli-responsive drug delivery system,SSDDS has remarkable advantages including feedback regulation,stronger controllability and targeting therapy.This paper will review the advancement in stimuli-responsive drug delivery system in recent years.
2.Correlations between the levels of glycosylated hemoglobin A1c and N-Terminal pro-Brain Natriuretic peptide in aged diabetes mellitus patients with heart failure
Chinese Journal of Primary Medicine and Pharmacy 2011;18(7):909-910
Objective To explore the correlations between the levels of glycosylated hemoglobin A1c (HbA1c)and N-Terminal pro-Brain Natriuretic peptide(NT-proBNP)in aged diabetes mellitus(DM)patients with heart failure(HF).Methods 127 patients diagnosed as DM complicated by HF and detected HbA1c and NT-proBNP when admitted into hospital,were divided into three groups according to the levels of HBA1C as follows:group A,4%≤HbA1c≤6.9%;group B,7%≤HbA1≤7.9%;group C,HbA1c≥8%.The levels of NT-proBNP were measured and compared.Results There was no statistical difference between group A and B(P>0.05),where as the levels of NT-proBNP in group C increased significantly than that in group A and B(P<0.01);In group C,HbA1c was linear positively correlated to NT-proBNP(r=0.558,P<0.01).Conclusion Aged DM patients complicated by HF,the level of HbA1c between 4%and 7.9%was acceptable.Meawhile,HhA1c should the independent risk prediction factor for aged DM patients complicated by HF,which could be used as the guide to the clinical therapy to improve the prognosis.
3.Advance of mini-invasive treatments of hepatic portal hypertension in cirrhosis
Journal of Medical Postgraduates 2003;0(05):-
The therapeutic management of hepatic portal hypertension in patients with cirrhosis is still a challenge. At present surgical devascularization and shunting play the important roles in treatment of portal hypertension. While some cirrhotic patients can not bear the stress of operation and anesthesia because of inadequat potential hepatic function. So the mortality of operation is very high. With the development of endoscopy,radiological techniques and new materials and equipments, the mini invasive treatments become more important. This review summarizes the current advances of mini invasive treatments of portal hypertension in cirrhosis.
4.Experimental study of arsenic trioxide on rabbits with hepatic Vx-2 carcinoma by transcatheter arterial infusion
Journal of Third Military Medical University 2003;0(16):-
Objective To evaluate the anticancer effect of arsenic trioxide (As 2O 3) on rabbits with hepatic Vx 2 carcinoma by transcatheter arterial infusion (TAI). Methods Rabbits with hepatic Vx 2 carcinoma were treated with As 2O 3 by TAI for 7 d consecutively. The tumor inhibitory rate and the average tumor weight were determined. The morphological changes of the tumor were observed with a transmission electron microscope. bax/bcl 2 and VEGF expressions were examined by immunohistochemistry. Results The average weight of the tumor was 7.99, 6.50, and 4.87 g, and the tumor growth inhibitory rates in the experimental groups were 50.31%, 59 58%, and 69 71%, respectively. Tumor growth was significantly inhibited as compared with that in the NS group ( P
5.The research status of preclinical animal experiments of gene therapy for Leber congenital amaurosis
Chinese Journal of Experimental Ophthalmology 2014;32(8):764-768
Leber congenital amaurosis (LCA) is extremely severe hereditary retinal dystrophy,because it leads to congenital bilateral blindness in early childhood.With the development of molecular genetics and the therapeutic gene replacement technology,gene therapy clinical trials have obtained exciting results on the basis of relatively satisfied with preliminary clinical experimental results by adeno-associated virus (AAV) vector-mediated gene therapy in the past decade.These researching methods include intravitreal injection and subretinal space injection of gene vector,and the investigating indexes include evaluations of visual function and safety,such as immune reaction of the animals,ocular histopathological change,complications and bio-distribution of gene sequence.The preliminary success of the LCAⅡ Ⅱ gene therapy will give some clues to the other inherited retinal diseases.This review focuses on the present status of pre-clinical animal experiments of its gene therapy.
7.Advances in therapeutic options for peripheral T-cell lymphomas
Chinese Journal of Radiation Oncology 2017;26(5):588-592
Peripheral T-cell lymphoma (PTCL) is a highly specific and invasive non-Hodgkin's lymphoma derived from mature T-cells that leave the thymus.At present, the clinical progress in PTCLs is behind that in B-cell lymphomas, and the current treatments for PTCLs have low efficacy and poor overall prognosis.Therefore, there is currently still no standard treatment for PTCL.The efficacy of the conventional CHOP chemotherapy regimen is poor, and the value of radiotherapy in early-stage PTLC patients remains to be determined.Autologous hematopoietic stem cell transplantation is the top choice for consolidation treatment for high-risk patients, but the efficacy of novel drugs for PTCLs needs to be further confirmed.In addition, PET/CT plays a more important role in predicting the prognosis of PTCLs.
8.Advances in the research of carrier materials for implant drug delivery system within bone
International Journal of Biomedical Engineering 2006;0(06):-
Implant drug delivery system(IDDS) is helpful to the therapy of infection、tuberculosis and tumor of bone. With the development of tissue engineering, various materials has been used as the carriers for the IDDS. Research of the carrier materials used in implant drug delivery system is reviewed in this article.
9.Clinical progress of anti-epidermal growth factor receptor antibody,cetuximab,in the treatment of colorectal cancer
Chinese Journal of Clinical Pharmacology and Therapeutics 2004;0(07):-
Recent clinical trials suggested that epidermal growth factor receptor (EGFR) targeted agents could benefit many patients with colorectal cancer. This article reviews the clinical efficacy of cetuximab, which is an antibody directed at the EGFR, in the treatment of metastatic colorectal carcinoma. Several articles about EGFR-targeted therapies in metastatic colorectal carcinoma and other solid tumors were reviewed. Cetuximab showed the increase in progression-free survival (3.98 months vs 2.56 months, P
10.The portable low power military ECG for triage
Chinese Medical Equipment Journal 2004;0(09):-
The military portable ECG for triage is a kind of minitype monitoring equipment for life information for the purpose that the ambulanceman carry through first aids in frontline. Life information of the wounded will be acquired exactly and quickly applying with this equipment, then quickening the triage and reducing the casualties. The system is based on C8051F310 single chip microcomputer, applying with high accuracy, low offset drift instrumentation amplifier AD620 and ultra low power LCM LMS019 to display real-time and accurate ECG signal sampled. The equipment is easy to use and inexpensive, suitable for mass requirement of our field army.